Standout Papers

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, do... 2022 2026 2023 2024126
  1. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial (2022)
    Kristian Reich, Jacob P. Thyssen et al. The Lancet

Immediate Impact

54 standout
Sub-graph 1 of 23

Citing Papers

OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target
2024 Standout
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
2024 Standout
1 intermediate paper

Works of Urs Kerkmann being referenced

A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis
2023
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
2022 Standout

Author Peers

Author Last Decade Papers Cites
Urs Kerkmann 347 127 66 224 23 521
Nicole Dumont 319 100 86 271 20 504
C. Pickard 193 109 135 223 15 579
Yangfeng Ding 227 60 73 294 40 490
William C. Ports 346 136 76 167 19 486
Hanne Norsgaard 379 53 131 405 23 635
Aleksandra Batycka-Baran 271 71 62 266 39 538
Deepak M.W. Balak 229 101 95 255 20 477
M Mattii 347 30 93 273 13 517
Giuseppina Caiazzo 262 72 57 249 31 525
Shiu-chung Au 276 85 100 397 20 607

All Works

Loading papers...

Rankless by CCL
2026